… As purine analogs, it is feasible that direct interaction of allopurinol or oxypurinol with
adenosine A receptors could account for anti-nocioception; however, this possibility requires …

… Previously, we described the effect of allopurinol and oxypurinol on hypoxanthine, xanthine,
and uric acid in neonates with HIE using a population PK-PD approach [16]. In that study, …

… The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of
dotinurad according to the type of hyperuricemia, with or without concomitant use of xanthine …

… The active allopurinol metabolite oxypurinol also is a substrate of this efflux … of oxypurinol
would predict higher oxypurinol concentrations and thus a higher effectiveness of allopurinol in …

… Previous in vitro data have suggested that febuxostat inhibits BCRP at clinically relevant
concentrations. By contrast, allopurinol and its metabolite oxypurinol have not inhibited BCRP in …

… Therefore the renal clearance of oxypurinol is therefore … clinical pharmacokinetics of
allopurinol (Day et al. 2007). Patients treated with allopurinol excrete 70% of the dose as oxypurinol …

… to oxypurinol, and … oxypurinol, which has a weak effect after the disappearance of this
covalent bond; thus, no compound has been developed with a more potent effect than allopurinol. …

… This study will assess the combined clinical effect of verinurad + allopurinol on kidney
function in patients with CKD, hyperuricaemia and albuminuria, and whether this combination …

… data (eg, age, body weight, and medications) from electrical medical records. We checked
concurrent medications known to affect oxypurinol concentration such as uricosuric agent and …

… assess whether exposure to oxypurinol, the active metabolite of allopurinol, predicts change
… to receive allopurinol (n=185) or placebo (n=184). Plasma oxypurinol concentrations were …